[{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AV-380","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AV-380","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Biodesix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Biodesix"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Biodesix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Biodesix","highestDevelopmentStatusID":"8","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Biodesix"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Undisclosed","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tivozanib HCl","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor | Stem cell growth factor receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tivozanib HCl","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tivozanib HCl","moa":"Platelet-derived growth factor receptor beta | Vascular endothelial growth factor receptor | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"AV-203","moa":"Receptor tyrosine-protein kinase erbB-3","graph1":"Oncology","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Parexel | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Parexel | Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Parexel | Bristol Myers Squibb"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Undisclosed"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Astellas Pharma"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"AVEO Pharmaceuticals, Inc \/ AstraZeneca"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"8","companyTruncated":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"1","companyTruncated":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"8","companyTruncated":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"8","companyTruncated":"AVEO Pharmaceuticals, Inc \/ AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"Julie E. Bauman","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AVEO Pharmaceuticals, Inc \/ Julie E. Bauman","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ Julie E. Bauman"},{"orgOrder":0,"company":"AVEO Pharmaceuticals, Inc","sponsor":"James J. Lee","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Ficlatuzumab","moa":"Hepatocyte growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"AVEO Pharmaceuticals, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AVEO Pharmaceuticals, Inc \/ James J. Lee","highestDevelopmentStatusID":"10","companyTruncated":"AVEO Pharmaceuticals, Inc \/ James J. Lee"}]
Find Clinical Drug Pipeline Developments & Deals by AVEO Pharmaceuticals, Inc
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
